UNIVERSITE DE VERSAILLES ST QUENTIN EN YVELINES Patent applications |
Patent application number | Title | Published |
20140249204 | IDENTIFICATION OF A JAK2 MUTATION IN POLYCYTHEMIA VERA - The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group. | 09-04-2014 |
20130189683 | IDENTIFICATION OF A JAK2 MUTATION INVOLVED IN VAQUEZ POLYGLOBULIA - The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group. | 07-25-2013 |
20130164762 | PROGNOSTIC TEST OF THE PROGRESSION OF A SOLID TUMOUR BY IMAGE ANALYSIS - The present invention relates to a method for the prognosis of the progression of a solid tumour in a patient, which includes at least the following steps: a) making, from a tumour sample, a virtual slide on which a tumour front can be identified; b) quantifying, on said virtual slide made in step a), the density of cells and/or blood vessels present in a continuous area covering the tumour front and extending on either side of the tumour front over a distance of at least 0.5 mm, referred to as the quantification area; and c) deducing, from said quantification, the risks of postoperative relapse and/or the sensitivity to various antitumor treatments and/or the risks of developing metastases in said patient. Preferably, the cells to be quantified are leukocytes, such as T cells, B cells, macrophages, natural killer cells, dendritic cells, or subpopulations of these immune system cells. | 06-27-2013 |
20100244657 | HALL EFFECT ION EJECTION DEVICE - The disclosure relates to a Hall-effect ion ejection device that comprises a longitudinal axis substantially parallel to the ion ejection direction, and comprises at least: a main ionization and acceleration annular channel, the annular channel being open at its end; an anode extending inside the channel; a cathode extending outside the channel at the outlet thereof; a magnetic circuit for generating a magnetic field in a portion of the annular channel, said circuit including at least an annular inner wall, an annular outer wall and a bottom connecting the inner and outer annular walls and defining the downstream portion of the magnetic circuit; characterised in that the magnetic circuit is arranged so as to create at the outlet of the annular channel a magnetic field independent from the azimuth. | 09-30-2010 |